The Velogene (VEL) genomic assay is a qualitative DNA probe for vanA and vanB in enterococci. 150 clinical isolates were tested with the VEL assay and characterized by pigment production, catalase levels, motility, growth in 6 g of vancomycin/ml, vancomycin and teicoplanin susceptibility, API 20S assay, and genotyping by multiplex PCR. The VEL assay identified all enterococcal strains with vanA and vanB genes.During the last three decades, the prevalence of enterococci as nosocomial pathogens has been increasing. Vancomycinresistant enterococci (VRE) were first recognized in 1986 (4) and are now a worldwide clinical problem, especially in acute care hospitals and intensive care units (3).There are three predominant genotypes of VRE (2). The VanA gene confers high-level vancomycin resistance (vancomycin MIC Ն 64 g/ml), with accompanying teicoplanin resistance (Ͼ16 g/ml). The vanB gene confers low-to high-level vancomycin resistance (vancomycin MICs between 16 and Ն1,000 g/ml) and no teicoplanin resistance. Both vanA and vanB are acquired and transferable and are most commonly seen in Enterococcus faecalis and E. faecium. VanC1 (associated with E. casseliflavus), vanC2 (associated with E. gallinarum), and vanC3 (associated with E. flavescens) confer intrinsically low-level vancomycin resistance (3, 6).Conventional testing with the vancomycin screen agar containing 6 g of vancomycin/ml and conventional vancomycin susceptibility tests do not reliably differentiate between vanC and low-level vanB resistance. Identification of the isolated species of VRE requires a minimum of 18 to 24 h. Hospitals that would implement infection control measures to control VRE with vanA and vanB genes, but not those with vanC genes, need the differentiation. Homebrew PCR assays may detect resistance genes, but they are available only to those laboratories with the expertise to develop their own tests. An efficient, simple, and reliable test to differentiate genotypes would help rapid treatment and initiation of appropriate infection control procedures (3).The Velogene (VEL) assay (ID Biomed, Bothell, Wash.) is based on a cycling probe technology that can be used to detect small amounts of DNA (1). Bacterial DNA is released from cells by suspending 1 loopful of growth from an 18-to 24-h culture in a lysing reagent that contains 20 mM TES [N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid] (pH 6.8), 0.05% Triton X-100, 150 U of achromopeptidase/ml, and 50 U of mutanolysin/ml. The DNA is denatured at 95°C for 5 min. When the target DNA (vanA and vanB genes) is hybridized with a fluorescein-labeled, biotinylated DNA-RNA-DNA chimeric probe, the RNase H cleaves the RNA portion of the probe. The mixture is transferred into streptavidin-coated microwells, and the uncleaved probe (negative reaction) is detected with the addition of fluorescein antibody conjugated with horseradish peroxidase, which converts the substrate to a blue end product. A positive-reaction product is colorless. The results can be detected visually or by spectrophotom...